3:15pm – 3:45pm Acne, Robert Sidbury, M.D., F.A.A.D.
3:45pm – 4:15pm Atopic dermatitis, Robert Sidbury, M.D., F.A.A.D.
4:15pm – 5:00pm Dupixent: Sustained Results, Lasting Relief. For Patients 6 years of age with Moderate to Severe Atopic Dermatitis, Brett King, M.D., (product theater sponsored by Sanofi Genzyme and Regeneron) (non-CME)
Sunday, June 13, 2021 - 4 hours of CME Session 6 8:00am – 8:30am Cosmetic complications, Ronald Moy, M.D., F.A.A.D.
8:30am – 9:00am How well does thread lifts, microneedling (radiofrequency) and laser resurfacing work?, Ronald Moy, M.D., F.A.A.D.
9:00am – 9:25am Chemical peels and acne scars, Peter Rullan, M.D., F.A.A.D.
9:25am – 9:45am Botulinum toxin; fillers, and other injectables, Peter Rullan, M.D., F.A.A.D.
9:45am – 10:15am ILUMYA® (tildrakizumab-asmn): Consistent Efficacy With a Durable Safety Profile Through 5 Years. An IL-23 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis, Jashin J. Wu, M.D., F.A.A.D., (product theater sponsored by Sun Pharmaceuticals) (non-CME)
11:10am – 11:30pm Lasers, Victor Ross, M.D., F.A.A.D.
11:30pm – 11:55pm Radiofrequency, lifting, and tightening devices, Victor Ross, M.D., F.A.A.D.
11:55pm – 12:20pm Oral presentations of the top posters Brickell Biotech: An Open-Label, Repeat-Dose, Maximum-Use Study to Evaluate the Pharmacokinetics of Sofpironium Bromide Gel, 15% Topically Applied in Subjects with Primary Axillary Hyperhidrosis BMS: Selective Inhibition of Tyrosine Kinase 2 (TYK2) With Deucravacitinib Compared With Janus Kinase (JAK) 1–3 Inhibitors Castle Biosciences:Clinical usage data demonstrates appropriate utilization of the prognostic 40-gene expression profile (40-GEP) test for cutaneous squamous cell carcinoma (cSCC) Amylee Martin, BS: The risk of COVID-19 in patients with atopic dermatitis
12:20pm – 12:25pm Conference closing, Jashin J. Wu, M.D., F.A.A.D.